WHAT’S OUR STORY?

We are on a mission to impact patients’ lives.

We have potentially groundbreaking clinical-stage therapies in development that, if approved, offer an innovative approach to essential areas of dermatology.

OUR STORY STARTS HERE

We are proud to announce the FDA approval of our first treatment
WINLEVI® (clascoterone) cream 1%

Read more

LATEST NEWS

April 29, 2021
chevron right icon

Cassiopea Announces Results of AGM 2021

April 21, 2021
chevron right icon

Lists of Candidates for the Board of Directors at the AGM 2021

March 25, 2021
chevron right icon

Cassiopea Reports Year End 2020 Results

Breezula is under investigation in the United States for the treatment of androgenetic alopecia, and the safety and efficacy have not been established by the United States Food and Drug Administration (FDA). The proposed brand name for clascoterone solution 7.5% is not FDA-approved.